

Table 11.6i
Immunosuppression Use for Antirejection Treatment from Transplant
to One Year Following Transplantation, 1999 to 2008
Recipients with Heart Transplants

| | Year of Transplant | | | | | | | | | |
|---|--------------------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| | 1999 | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 |
| Transplants | 2,188 | 2,199 | 2,202 | 2,155 | 2,057 | 2,015 | 2,125 | 2,193 | 2,209 | 2,163 |
| Tx with Antirejection Treatments | 916 | 902 | 849 | 803 | 656 | 533 | 533 | 485 | 430 | 382 |
| Antibodies | | | | | | | | | | |
| Any in Category | 17.7% | 16.4% | 15.5% | 17.4% | 18.4% | 15.6% | 18.0% | 19.2% | 17.0% | 19.9% |
| Atgam/NRATG/NRATS | 6.3% | 4.7% | 3.9% | 4.0% | 4.6% | 2.6% | 2.4% | 3.5% | 5.1% | 5.0% |
| OKT3 | 7.4% | 5.1% | 5.8% | 6.8% | 4.1% | 3.2% | 3.4% | 3.7% | 1.4% | 2.9% |
| Thymoglobulin | 2.0% | 3.8% | 4.9% | 6.4% | 7.5% | 8.6% | 9.4% | 11.1% | 9.3% | 11.5% |
| Zenapax | 2.5% | 3.0% | 2.5% | 1.5% | 2.0% | 1.5% | 3.6% | 1.6% | 2.6% | 2.6% |
| Simulect | 0.9% | 2.0% | 0.4% | 0.4% | 1.4% | 0.6% | 0.8% | 0.2% | 0.2% | 0.0% |
| Campath | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.2% | 0.2% | 0.2% | 0.0% | 0.3% |
| Corticosteroids | | | | | | | | | | |
| Any in Category | 91.3% | 92.4% | 92.7% | 92.2% | 92.5% | 91.4% | 90.8% | 90.5% | 89.5% | 90.3% |
| Steroids | 91.3% | 92.4% | 92.7% | 92.2% | 92.5% | 91.4% | 90.8% | 90.5% | 89.5% | 90.3% |
| Antimetabolites | | | | | | | | | | |
| Any in Category | 4.6% | 4.4% | 2.0% | 3.0% | 3.5% | 1.7% | 2.3% | 1.9% | 2.3% | 1.8% |
| Cytoxin | 2.1% | 1.7% | 0.5% | 0.9% | 1.7% | 1.3% | 1.3% | 1.6% | 2.1% | 1.3% |
| Methotrexate | 2.6% | 2.8% | 1.5% | 2.1% | 1.8% | 0.4% | 0.9% | 0.2% | 0.2% | 0.5% |

Source: OPTN/SRTR Data as of October 1, 2010.

Notes:

Individual drug percentages will not necessarily add up to the drug category percentages, as patients may be prescribed more than one drug within the same category.